LEO orders Hitgen to discover new leads
In a multi-year collaboration with LEO Pharma A/S, Chinese Hitgen is poised to discover novel small molecule leads for multiple therapeutic targets chosen by the Danish skin treatment specialist.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2153 entries already.
Entries by Thomas Gabrielczyk
Vernalis receives next veto by FDA
British biotech company Vernalis has to deal with another Complete Response Letter by US authority FDA – this time regarding the New Drug Application for its cough and cold treatment CCP-08.
Hansa’s immunomodulatory enzyme does the job
Sweden’s Hansa Medical AB presented data showing its experimental drug allowed doctors to perform successful kidney transplants in patients with a particularly high risk of organ rejection.
TC Biopharm gets €4m Horizon2020 grant
The Scottish biotech company TC Biopharm (TCB) has been awarded a €4m grant from the European Union’s Horizon 2020 programme.
Zealand taps US market
Danish diabetes biotech Zealand Pharma has started its initial public offering in the US at Nasdaq Global Select Market. It plans to raise US$75m to fund clinical trails.
Uniqure from now on alone
Italian pharma company Chiesi Farmaceutici withdraws from a co-development agreement with gene therapy pioneer Uniqure. This will add US$1.5m to Uniqure’s expenses this year.
Orphan drugs: Treating a rarity
Since US senators in February conveyed the impression that drug developers might have misused market monopolies related to orphan drugs (ODs) to overprice their compounds, the status has come under closer scrutiny. Neither the US nor Europe currently have consistent approaches for deriving value for OD therapies. Pooling expertise and scattered patient data across borders could help ease both diagnosis and development, providing a foundation for pricing and giving patients much faster access to treatments.
Neovacs raises €6m through private placement
French immunotherapy specialist Neovacs raises 6€m from three US institutional investors. The private placement involves the issuance of more than 9 million shares.
J&J intensifies vaccine endeavour with Bavarian Nordic
Johnson & Johnson has entered a new deal with Danish biotech Bavarian Nordic worth up to US$879m to develop vaccine regimens against hepatitis B and HIV.
GSK cancels 30 preclinical and clinical programmes
UK’s biggest pharma firm announced it will save an additional £1bn each year by 2020. 80% of the pharmaceutical R&D pipeline expenses will be directed towards two current (Respiratory and HIV/infectious diseases) and two potential (Oncology and Immuno-inflammation) priority areas.